***Background.*** Probiotics are live microorganisms that confer a health benefit when ingested. The dietary supplement ProNutrients® Probiotic contains the probiotics LGG and BB-12 in a powder sachet. The objectives of this study were to confirm the survival and recovery of the organisms from the GI tract of healthy volunteers after ingestion of the supplement and to assess safety.

***Methods.*** This was a 2 arm, parallel group, open label randomized prospective study of healthy volunteers. All subjects underwent a run-in period (\> 14 days). Thereafter, the subjects were randomized to a non-supplemented control group (C) or the probiotic (P) group, which consumed 1 sachet of supplement (S) containing \> 1x10^9^ colony forming units (CFU) of each organism/day for 21 days. There was a 28 days post-S period. Fecal samples were collected at baseline (the end of the run-in period), and after 14, 21, and 28 days. LGG and BB-12 were quantified by (1) quantitative culture (qCX) with colony ID confirmed by polymerase chain reaction (PCR) and (2) qPCR. The primary endpoint was the recovery of LGG and BB-12 (CFU/g) from the fecal samples of all subjects at 21 days. CFU were log~10~ transformed. Paired t-tests were used to compare within subjects change from baseline. ANOVA models with a treatment term were used to compare groups.

***Results.*** 27 subjects (13 males and 14 females) were randomized and included in the analysis. The Table shows results for recovery of LGG and BB-12 by qCX at 21 days Similar results were obtained at 14 days and for recovery by qPCR at 14 and 21 days.

                                   LGG         BB-12                     
  -------------------------------- ----------- ------------- ----------- -------------
  **Baseline**                                                           
  Mean (SD) log~10~ CFU/g sample   3.5 (0.6)   3.4\* (0.0)   5.4 (0.0)   5.4\* (0.0)
  **21 days after baseline**                                             
  Mean (SD)                        5.5 (1.7)   3.4\* (0.0)   7.2 (1.1)   5.4\* (0.0)
  **p-value 21 d vs baseline**     \< 0.001    \-            \< 0.001    \-
  **p-value P vs C**               0.006       \<0.001                   

\*Lower limit of detection.

6 subjects (31.6%), all in the P group, reported 14 mild and 7 moderate severity adverse events (AE). The 2 treatment-related AEs were mild: diarrhea and abdominal distension, each in 1 subject.

***Conclusion.*** Few studies have examined the recovery of viable organisms after ingestion of probiotic combinations. Here we demonstrate the recovery of viable LGG and BB-12 from the GI tract of healthy volunteers who consumed this probiotic product matrix. The supplement was well tolerated.
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